Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 50

Results For "study"

1396 News Found

Innovent Biologics’ experimental weight-loss drug achieves breakthrough in Phase 3 trial
Clinical Trials | November 21, 2025

Innovent Biologics’ experimental weight-loss drug achieves breakthrough in Phase 3 trial

Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration


Roche’s Giredestrant sets new benchmark in early breast cancer treatment
Clinical Trials | November 19, 2025

Roche’s Giredestrant sets new benchmark in early breast cancer treatment

The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival


Cardiol Therapeutics wins US patent protection for heart-disease drug platform
News | November 19, 2025

Cardiol Therapeutics wins US patent protection for heart-disease drug platform

The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38


Galmed’s Aramchol shows promise in overcoming gastrointestinal cancer drug resistance
Clinical Trials | November 18, 2025

Galmed’s Aramchol shows promise in overcoming gastrointestinal cancer drug resistance

Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma


Samson Clinical completes patient recruitment for clinical trial of male-pattern baldness drug
Clinical Trials | November 17, 2025

Samson Clinical completes patient recruitment for clinical trial of male-pattern baldness drug

AGA affects up to 80 per cent of men across their lifetime and remains one of the most common and most psychologically challenging forms of hair loss


Cenmed and Curavit team up to revolutionize clinical trial logistics
Supply Chain | November 16, 2025

Cenmed and Curavit team up to revolutionize clinical trial logistics

This collaboration turns kitting into a strategic advantage for sponsors and sites


Merck to acquire Cidara Therapeutics for $9.2 billion
Biotech | November 15, 2025

Merck to acquire Cidara Therapeutics for $9.2 billion

Diversifying its portfolio to include late-phase antiviral agent